APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
-1.01%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$4.36B
AUM Growth
+$4.36B
(-3.3%)
Cap. Flow
+$173M
Cap. Flow
% of AUM
3.97%
Top 10 Holdings %
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
19
Top Buys
| 1 |
Eli Lilly
LLY
|
$198M |
| 2 |
argenx
ARGX
|
$150M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$107M |
| 4 |
Humana
HUM
|
$99.9M |
| 5 |
Johnson & Johnson
JNJ
|
$97M |
Top Sells
| 1 |
Merck
MRK
|
$194M |
| 2 |
Baxter International
BAX
|
$149M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$146M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$115M |
| 5 |
AbbVie
ABBV
|
$109M |
Sector Composition
| 1 | Healthcare | 95.35% |
| 2 | Financials | 0.54% |
| 3 | Technology | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Legend Biotech
LEGN
$6.63B
| $55M | 1.26% |
1,000,000
-95,000
| -9% | -$5.23M |
|
27
Arrowhead Research
ARWR
$3.74B
| $50.7M | 1.16% |
1,438,999
+483,999
| +51% | +$17M |
|
28
Immunocore
IMCR
$1.72B
| $50.4M | 1.16% |
1,350,000
-13,800
| -1% | -$515K |
|
29
Natera
NTRA
$22.8B
| $48.5M | 1.11% |
1,369,100
+69,100
| +5% | +$2.45M |
|
|
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $44.3M | 1.02% |
+775,504
| New | +$44.3M |
|
31
IDEAYA Biosciences
IDYA
$2.25B
| $41M | 0.94% |
2,972,947
+282,947
| +11% | +$3.9M |
|
|
BLU
32
DELISTED
BELLUS Health Inc.
BLU
| $39.4M | 0.9% |
4,265,000
+580,000
| +16% | +$5.36M |
|
33
Altimmune
ALT
$327M
| $34.9M | 0.8% |
2,981,000
+116,000
| +4% | +$1.36M |
|
34
Kezar Life Sciences
KZR
$28.6M
| $33.5M | 0.77% |
4,050,000
+532,000
| +15% | +$4.4M |
|
35
Avidity Biosciences
RNA
$6.03B
| $30.2M | 0.69% |
2,080,200
+35,200
| +2% | +$511K |
|
|
KRTX
36
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $25.9M | 0.59% |
+204,570
| New | +$25.9M |
|
37
Revolution Medicines
RVMD
$7.42B
| $25.8M | 0.59% |
+1,325,000
| New | +$25.8M |
|
38
ARK Genomic Revolution ETF
ARKG
$1.04B
| $23.6M | 0.54% |
+750,000
| New | +$23.6M |
|
39
Vir Biotechnology
VIR
$746M
| $19.3M | 0.44% |
758,211
-21,789
| -3% | -$555K |
|
40
Nkarta
NKTX
$150M
| $17.4M | 0.4% |
+1,414,082
| New | +$17.4M |
|
41
Phathom Pharmaceuticals
PHAT
$846M
| $16.2M | 0.37% |
1,919,800
-26,200
| -1% | -$221K |
|
42
Caribou Biosciences
CRBU
$175M
| $16M | 0.37% |
2,950,000
+130,933
| +5% | +$711K |
|
|
DCPH
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $15.8M | 0.36% |
+1,200,000
| New | +$15.8M |
|
44
Nuvation Bio
NUVB
$1.05B
| $15.7M | 0.36% |
4,855,000
-6
| -0% | -$19 |
|
45
Iovance Biotherapeutics
IOVA
$796M
| $15.4M | 0.35% |
1,392,300
-4,650,919
| -77% | -$51.3M |
|
46
Xenon Pharmaceuticals
XENE
$3.01B
| $13.7M | 0.31% |
+450,000
| New | +$13.7M |
|
47
SI-BONE Inc
SIBN
$698M
| $13.2M | 0.3% |
1,000,000
| – | – |
|
|
SPNE
48
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $11.4M | 0.26% |
2,010,000
| – | – |
|
49
Alphatec Holdings
ATEC
$2.31B
| $11.2M | 0.26% |
1,715,000
-1,020,600
| -37% | -$6.67M |
|
50
Apellis Pharmaceuticals
APLS
$3.51B
| $9.72M | 0.22% |
215,000
+5,000
| +2% | +$226K |
|